Denmark· DK-28106239319
Zeposia
A ozanimod product containing ozanimodhydrochlorid, registered in Denmark by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 13 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Ozanimod is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AE02 (ozanimod), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Ozanimod · ATC L04AE02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ozanimod costs, country by country.
Normalised to the WHO defined daily dose (0.92 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ozanimod · price per daily dose (0.92 mg)
USD · FX 28 Sept 2026
- CH Switzerland$85.78
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Ozanimodhydrochlorid
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Denmark (DK)
- ATC code
- L04AE02
- ATC class
- Ozanimod
- Defined daily dose
- 0.92 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106239319
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
852 interactions on record for ozanimod.
Graded by severity as the source publishes them — 578 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ozanimod · interactions on record
852 records
- 578 severe
- 271 moderate
- 3 minor
Most severe, free to view
- FamotidineA02BA03severe
- PapaverineA03AD01severe
- IsomethepteneA03AX10severe
- CisaprideA03FA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L04AE02
Ozanimod, as other registers publish it.
- IcelandZeposiaBristol-Myers Squibb Pharma EEIG*
- NorwayZeposiaBristol-Myers Squibb Pharma EEIG (1)
- NorwayZeposiaBristol-Myers Squibb Pharma EEIG (1)
- NorwayZeposiaBristol-Myers Squibb Pharma EEIG (1)
- FinlandZeposiaBristol-Myers Squibb Pharma EEIG
- FinlandZeposiaBristol-Myers Squibb Pharma EEIG
- IcelandZeposiaBristol-Myers Squibb Pharma EEIG*
- CzechiaZEPOSIABristol-Myers Squibb Pharma EEIG, Dublin
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d5725f50-3d7c-4d51-99ff-fb9aad80dcf1 GET /v1/drugs/d5725f50-3d7c-4d51-99ff-fb9aad80dcf1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "kapsler, hårde",
"source": "dkma",
"strength": "0,92 mg",
"auth_role": "MOD",
"dk_drugid": "28106239319",
"substance": "Ozanimodhydrochlorid",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "43971"
}See everything about ozanimod.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.